196 related articles for article (PubMed ID: 34652310)
1. Echographic Assessment of Extraocular Muscle Response to Teprotumumab.
Tran C; Pham CM; Simmons BA; Warner LL; Fuhrmeister LJ; Shriver EM
Ophthalmic Plast Reconstr Surg; 2022 Jul-Aug 01; 38(4):336-339. PubMed ID: 34652310
[TBL] [Abstract][Full Text] [Related]
2. Reduction in Extraocular Muscle Cross-sectional Area and Correlation With Extraocular Motility and Diplopia Following Teprotumumab for Thyroid Eye Disease.
Reshef ER; Marsiglia M; Bouhadjer K; Chiou CA; O'Brien-Coon D; Reinshagen KL; Freitag SK
Ophthalmic Plast Reconstr Surg; 2023 Sep-Oct 01; 39(5):433-439. PubMed ID: 36852831
[TBL] [Abstract][Full Text] [Related]
3. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
[TBL] [Abstract][Full Text] [Related]
4. Teprotumumab and Orbital Decompression for the Management of Proptosis in Patients With Thyroid Eye Disease.
Hubschman S; Sojitra B; Ghiam S; Sears C; Hwangbo N; Goldberg RA; Rootman DB
Ophthalmic Plast Reconstr Surg; 2024 May-Jun 01; 40(3):270-275. PubMed ID: 37972968
[TBL] [Abstract][Full Text] [Related]
5. Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease.
Jain AP; Gellada N; Ugradar S; Kumar A; Kahaly G; Douglas R
Br J Ophthalmol; 2022 Feb; 106(2):165-171. PubMed ID: 33172865
[TBL] [Abstract][Full Text] [Related]
6. Teprotumumab for the Treatment of Active Thyroid Eye Disease.
Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ
N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679
[TBL] [Abstract][Full Text] [Related]
7. Teprotumumab for the Treatment of Recalcitrant Thyroid Eye Disease.
Men CJ; Amarikwa L; Pham B; Sears C; Clauss K; Lee BW; Lee WW; Pasol J; Ugradar S; Shinder R; Cockerham K; Wester S; Douglas R; Kossler AL
Ophthalmic Plast Reconstr Surg; 2024 May-Jun 01; 40(3):276-285. PubMed ID: 37972960
[TBL] [Abstract][Full Text] [Related]
8. Graves' ophthalmopathy: eye muscle involvement in patients with diplopia.
Nagy EV; Toth J; Kaldi I; Damjanovich J; Mezosi E; Lenkey A; Toth L; Szabo J; Karanyi Z; Leovey A
Eur J Endocrinol; 2000 Jun; 142(6):591-7. PubMed ID: 10832104
[TBL] [Abstract][Full Text] [Related]
9. A comparison of proptosis reduction with teprotumumab versus surgical decompression based on fat-to-muscle ratio in thyroid eye disease.
Ting MAJ; Topilow NJ; Ediriwickrema LS; Yoon JS; Liu CY; Korn BS; Kikkawa DO
Orbit; 2024 Apr; 43(2):222-230. PubMed ID: 37978819
[TBL] [Abstract][Full Text] [Related]
10. Teprotumumab-Related Adverse Events in Thyroid Eye Disease: A Multicenter Study.
Shah SA; Amarikwa L; Sears CM; Clauss KD; Rajjoub RD; Kang JY; Tamhankar MA; Briceño CA; Harrison AR; Dosiou C; Cockerham KP; Wester ST; Douglas RS; Kossler AL
Ophthalmology; 2024 Apr; 131(4):458-467. PubMed ID: 37852417
[TBL] [Abstract][Full Text] [Related]
11. Improvement of asymmetric thyroid eye disease with teprotumumab.
Ugradar S; Wang Y; Mester T; Kahaly GJ; Douglas R
Br J Ophthalmol; 2022 Jun; 106(6):755-759. PubMed ID: 33579690
[TBL] [Abstract][Full Text] [Related]
12. Real-World Experience With Teprotumumab in Patients With Dysthyroid Optic Neuropathy.
Tamhankar MA; Pradeep T; Chen Y; Briceño CA
J Neuroophthalmol; 2024 Mar; 44(1):74-79. PubMed ID: 37751310
[TBL] [Abstract][Full Text] [Related]
13. Objective Diplopia Outcomes for Patients Treated With Teprotumumab for Thyroid Eye Disease.
Mudalegundi S; Huang P; Henderson AD; Carey AR
J Neuroophthalmol; 2024 Mar; 44(1):80-86. PubMed ID: 38294416
[TBL] [Abstract][Full Text] [Related]
14. Clinical challenge: An orbital Hickam's dictum.
Wilson ME; Thornton S; Murchison AP; Bilyk JR
Surv Ophthalmol; 2016; 61(6):799-805. PubMed ID: 26994869
[TBL] [Abstract][Full Text] [Related]
15. Re: "Reduction in Extraocular Muscle Cross-sectional Area and Correlation With Extraocular Motility and Diplopia Following Teprotumumab for Thyroid Eye Disease".
Ting MAJ; Liu CY; Korn BS; Kikkawa DO
Ophthalmic Plast Reconstr Surg; 2023 Jul-Aug 01; 39(4):396-397. PubMed ID: 37413681
[No Abstract] [Full Text] [Related]
16. Customized Orbital Decompression Surgery Combined with Eyelid Surgery or Strabismus Surgery in Mild to Moderate Thyroid-associated Ophthalmopathy.
Choi SW; Lee JY; Lew H
Korean J Ophthalmol; 2016 Feb; 30(1):1-9. PubMed ID: 26865797
[TBL] [Abstract][Full Text] [Related]
17. Reply Re: "Reduction in Extraocular Muscle Cross-sectional Area and Correlation With Extraocular Motility and Diplopia Following Teprotumumab for Thyroid Eye Disease".
Reshef ER; Marsiglia M; Bouhadjer K; Chiou CA; O'Brien-Coon D; Reinshagen KL; Freitag SK
Ophthalmic Plast Reconstr Surg; 2023 Jul-Aug 01; 39(4):397. PubMed ID: 37413682
[No Abstract] [Full Text] [Related]
18. Influence of orbital morphology on proptosis reduction and ocular motility after decompression surgery in patients with Graves' orbitopathy.
Oeverhaus M; Copei A; Mattheis S; Ringelstein A; Tiemessen M; Esser J; Eckstein A; Stähr K
PLoS One; 2019; 14(6):e0218701. PubMed ID: 31233522
[TBL] [Abstract][Full Text] [Related]
19. Investigations of ocular changes, extraocular muscle thickness, and eye movements in Graves' ophthalmopathy.
Jankauskiene J; Imbrasiene D
Medicina (Kaunas); 2006; 42(11):900-3. PubMed ID: 17172791
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of teprotumumab therapy in patients with long-duration thyroid eye disease.
Subramanian PS; Cho RI; Kahana A
Curr Opin Ophthalmol; 2023 Nov; 34(6):487-492. PubMed ID: 37610428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
